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Background: Dormant cells are characterised by low RNA synthesis. In contrast, cancer cells can be addicted to
high RNA synthesis, including synthesis of survival molecules. We hypothesised that dormant cancer cells, already
low in RNA, might be sensitive to apoptosis induced by RNA Polymerase II (RP2) inhibitors that further reduce RNA
synthesis.
Methods: We cultured leukaemia cells continuously in vitro in the presence of an mTOR inhibitor to model
dormancy. Apoptosis, damage, RNA content and reducing capacity were evaluated. We treated dormancy-enriched
cells for 48 hours with the nucleoside analogues ara-C, 5-azacytidine and clofarabine, the topoisomerase targeting
agents daunorubicin, etoposide and irinotecan and three multikinase inhibitors with activity against RP2 -
flavopiridol, roscovitine and TG02, and we measured growth inhibition and apoptosis. We describe use of the
parameter 2 × IC50 to measure residual cell targeting. RNA synthesis was measured with 5-ethynyl uridine. Drug-
induced apoptosis was measured flow cytometrically in primary cells from patients with acute myeloid leukaemia
using a CD34/CD71/annexinV gating strategy to identify dormant apoptotic cells.
Results: Culture of the KG1a cell line continuously in the presence of an mTOR inhibitor induced features of
dormancy including low RNA content, low metabolism and low basal ROS formation in the absence of a DNA
damage response or apoptosis. All agents were more effective against the unmanipulated than the dormancy-
enriched cells, emphasising the chemoresistant nature of dormant cells. However, the percentage of cell reduction
by RP2 inhibitors at 2 × IC50 was significantly greater than that of other agents. RP2 inhibitors strongly inhibited
RNA synthesis compared with other drugs. We also showed that RP2 inhibitors induce apoptosis in proliferating
and dormancy-enriched KG1a cells and in the CD71neg CD34pos subset of primary acute myeloid leukaemia cells.
Conclusion: We suggest that RP2 inhibitors may be a useful class of agent for targeting dormant leukaemia cells.
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Relapse in cancer patients after therapy is due to the
continued presence of a subset of cells which is likely to
have evaded the effects of treatment by lying dormant
[1,2]. Dormant cells are characterised by low levels of
RNA, consistent with their lack of proliferation and need
to conserve energy [3]. However, cancer cells may be
dependent on (“addicted to”) survival gene expression
[4,5] and thus be primed for death if the survival genes
are down-regulated [6]. Hence we hypothesised that* Correspondence: monica.pallis@nottingham.ac.uk
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reproduction in any medium, provided the ordormant cancer cells, in which RNA levels are already
low, may be sensitive to agents that target the transcrip-
tional machinery. Transcriptional cyclin dependent
kinases, i.e. CDK9 and CDK7, are permissive for tran-
scription through modulation of the essential RNA
elongation factor RNA Polymerase II (RP2). RP2 serine
5 phosphorylation by CDK7 normally occurs early in the
initiation of transcription, whereas RP2 serine 2 phos-
phorylation by CDK9 predominates later, during elong-
ation and termination [7]. Inhibition of RP2, although
ultimately fatal to all cells, can allow for a therapeutic
window by selectively affecting molecules essential to
cancer cell survival. Foremost candidates for this role
are those molecules with a short message and proteind. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tors such as flavopiridol, roscovitine and TG02 inhibit
transcriptional CDKs and thus RP2 activation in cells
from patients with haematological malignancies [9-15].
A large amount of material is needed to study mecha-
nisms of drug targeting and resistance, but dormant can-
cer cells are rare. Thus in vitro models of the dormant
subpopulation would be valuable. In contrast to primary
samples, leukaemia cell lines are plentiful and highly
proliferative, so we sought a suitable method of inducing
dormancy in these cells.
MTOR is a critical mediator of cell cycle progression
[16,17]. In normal cells, mTOR integrates nutrient and
growth factor signals such that factor deprivation in-
hibits mTOR, allowing the cell to conserve resources,
quiesce and survive. This paper first addresses the
chemosensitivity of the KG1a cell line, which retains
long-term viability and is undamaged by mTOR inhibition.
We show that these cells, which have a CD34+CD38-,
p-glycoprotein+ phenotype characteristic of leukaemic pro-
genitor cells [18], are enriched for features of dormancy
by mTOR inactivation. We treat unmanipulated and
dormancy-enriched cells with the nucleoside analogues
ara-C, 5-azacytidine and clofarabine, the topoisomerase
targeting agents daunorubicin, etoposide and irinotecan
and three multikinase inhibitors with activity against RP2 -
flavopiridol, roscovitine and TG02. We report our findings
and extend them to primary leukaemia samples.
Methods
Materials
Phenotyping antibodies and isotype controls were
obtained from BD Biosciences. TG02-citrate was
synthesised by Tragara Pharmaceuticals. Other drugs
and reagents were obtained from Sigma unless otherwise
stated.
Cells and rapamycin pre-treatment
The KG1a myeloid leukaemia cell line was obtained
from the European Collection of Animal Cell Cultures
(Salisbury, UK) and was maintained in RPMI 1640
medium with 10% foetal calf serum (FCS; First Link,
Birmingham, UK) and 2 mM L-glutamine. All experi-
ments were performed with cell lines in log phase. Con-
tinued testing to authenticate the cells was performed by
genetic fingerprinting towards the final passage of each
batch thawed and through repeated assays of CD34,
CD38 and p-glycoprotein status. The cells were pre-
treated with rapamycin (LC labs) for 2–9 days before
addition of chemotherapy drugs.
Ethics statement
Blood or bone marrow samples were obtained after writ-
ten informed consent from AML patients. Use of thesesamples was approved by the Nottingham 1 Ethics Com-
mittee (reference 06/Q2403/16) and the Nottingham
University Hospitals NHS Trust. Frozen, banked samples
were used.
Drug treatment in cell lines
Unmanipulated and rapamycin-pre-treated KG1a cells were
pelleted and re-suspended in 96 well plates at 2 × 105 cells
per ml for 48 hours with and without drugs. Cytosine arabi-
noside (Ara-C), flavopiridol, irinotecan and daunorubicin
stock solutions were made in water. Clofarabine stock was
made in PBS. 5-azacytidine, etoposide, roscovitine (LC labs)
and TG02 were dissolved in DMSO as was the RP2 inhibi-
tor 5,6-dicholoro-1-β-D-ribofuranoslybenzimidazole (DRB).
DMSO diluent controls were used for etoposide and
roscovitine (because the final DMSO concentration was
greater than 1 in 10,000). Drug dilutions were made in cul-
ture medium.
Determination of RNA status and RNA synthesis
For flow cytometry, the method of Schmid was used
using 7-amino actinomycin D (7-AAD) to label DNA
and pyronin Y to label RNA [19]. RNA was also mea-
sured on unselected cells by spectrophotometry. RNA
synthesis was measured flow cytometrically using the
method of Jao and Salic [20]: 5-ethynyl uridine (EU,
Invitrogen) incorporation (20 μM, 1 hour) was followed
by detection with Alexa 488 azide (Invitrogen). A non-
specific fluorescence control tube, missing out the EU
incorporation step, was set up for each condition, and
the result subtracted from the test fluorescence value be-
fore calculating the percentage of untreated control
fluorescence for each drug.
To determine modulation of RP2S2, treated and un-
treated cells were fixed and permeabilized using the
Leucoperm kit (AbD Serotec) and were incubated with
antibodies to RP2S2 (Abcam #5095,) then with a FITC
conjugated second layer.
Determination of reactive oxygen species (ROS)
Cells were incubated with the (non-fluorescent) 15 μM
2′,7′-Dichlorofluorescin diacetate (DCFDA) in triplicate
for 25 minutes at 37°C and at 4°C, placed on ice and the
fluorescent oxidation product dichlorofluorescin (DCF)
was measured immediately by flow cytometry. Baseline
(4°C) values were subtracted from test (37°C) values.
Determination of metabolism
Cellular metabolism was measured using the reduction of
2,3-bis(2-methoxy-4-nitro5-sulfophenyl)-5-{(phenylamino)
carbonyl}-2H-tetrazolium hydroxide (XTT, Roche) [21].
Cells were plated at 2 × 105/ml and cultured for 48 hours,
with XTT for the final 6 hours. Relative absorbance was
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(measured by haemocytometer).
Immunocytochemistry
Gamma-H2A.X foci were identified and counted using
the H score system as previously described [22].
Determination of cell viability and apoptosis in cell lines
Toxicity was measured using the XTT assay kit
according to manufacturer’s instructions (Roche). Apop-
tosis was measured flow cytometrically using the
Trevigen Annexin V kit (R & D) according to manufac-
turers’ instructions.
Dormancy and apoptosis of primary AML cells
Primary cells were cultured in triplicate at 1 × 106/ml in
fibronectin coated wells of a flat-bottomed plate in
serum-free medium supplemented with cytokines. (A
previous publication [23] has further details). Drugs
were added after 2–3 hours. After 14–18 hours of fur-
ther culture, cells were harvested and stained with
CD34PerCP and CD45-APCCy7, and with CD71PE or
isotype controls. Following two rinses in PBS, the cells
were counterstained with Annexin V FITC in the buffer
provided (R&D Systems). CD71 expression was mea-
sured in cells gated tightly on forward and side scatter,
with secondary gating on CD45 and side scatter to ex-
clude lymphocytes. A third gate was set on CD34/low
side scatter and a fourth gate on annexin V low positive
cells. To ensure at most a 15% co-efficient of variation,
cultures with a low number of cells after this four-part
gating, i.e. less than 50 positive events, were excluded
(explained in detail elsewhere [24]).
Statistical analysis
Univariate analysis of variance main effects modelling
was used for comparing multiple treatments, and signifi-
cant findings were further analysed in 2 way compari-
sons using paired T-tests, carried out using the
Statistical Package for Social Sciences, version 16 (SPSS,
Chicago, IL, USA).
Results
mTOR inhibition induces the principal features of
dormant cells
Given that inhibition of the mTOR pathway is experi-
mentally proven to maintain the in vivo dormancy and
transplantability of haematopoietic and leukaemic cells
[25-28], we experimented with the possibility of
inhibiting growth in a leukaemic cell line with the
mTOR inhibitor rapamycin. In preliminary studies, we
cultured KG1a cells with 50-500 nM rapamycin and
found similar percentage growth inhibition across the
dose range (data not shown), such that 100 nM waschosen for further study. We now show that continuous
culture of KG1a cells in 100 nM rapamycin for up to
11 days induced no detectable apoptosis, whereas serum
withdrawal, the common method for inducing cells to
exit the cell cycle, induced a statistically significant in-
duction of Annexin V within 48 hours, and most cells
were dead within a week (Figure 1A,B). Sublethal dam-
age in the rapamycin-treated cells might sensitise them
to chemotherapeutic drugs, but we determined that no
measurable γH2A.X damage foci were induced by
rapamycin (Figure 1C).
We have already previously shown that rapamycin in-
hibits phosphorylation of the mTOR targets 4E-BP1 and
P70S6K in KG1a cells [29]. In a series of experiments
performed after 48 hours’ incubation with rapamycin we
found that, despite cell growth being slowed rather than
totally arrested by rapamycin, the cells acquired key
properties of dormant cells. There was a decrease in
RNA, measured as a 3.5fold increase in Pyronin Ylow
cells, from 13.6 to 48.6% cells and a decrease in total
RNA per cell of 54% (Figure 2A). This is an especially
important finding, as Pyronin Ylow cells are enriched for
dormancy rather than terminal differentiation as demon-
strated by their engraftment capacity in both normal
haematopoietic cells and tumour initiating cells [30,31].
We also observed a corresponding decrease in cell size
(Figure 2C) [3]. We noted that formazan production
from XTT, an indicator of mitochondrial metabolism,
was reduced by 34% in dormancy- enriched cells
(Figure 2D). We also noted a 32% ROS decrease in
dormancy-enriched cells (Figure 2E).
Superiority of transcriptional CDK/RP2 inhibitors in
targeting dormancy-enriched cells
As nucleoside analogues and topoisomerase inhibitors
are the mainstay of AML therapy, we examined the
toxicity of these drug classes as well as that of RP2
inhibitors against unmanipulated and dormancy-
enriched KG1a cells. We derived dose response curves
for the topoisomerase- targeting agents daunorubicin,
etoposide and irinotecan, nucleoside analogues ara-C, 5-
azacytidine and clofarabine and the transcriptional
CDK/RP2 inhibitors flavopiridol, roscovitine and TG02
in proliferating and dormancy-enriched KG1a cells. We
also used the specific RNA polymerase 2 inhibitor 5,6-
dicholoro-1-β-D-ribofuranoslybenzimidazole (DRB) as
positive control for RP2 targeting [4,32]. Figure 3A dem-
onstrates that dose response curves from dormancy-
enriched cells have a greater tendency than those from
unmanipulated cells to flatten out and there are more
residual cells under the flattened part of the curve. We
therefore asked a novel question: namely, how can we
measure the difficulty for a drug to target further cells
after the initial IC50 has been passed? For this measure,
Figure 1 Rapamycin is not toxic to KG1a cells. (A, B) KG1a cells were suspended/re-suspended at 2 × 105/ml on days 0,2,4,7 and 9 of an
11 day culture in medium with 0.5% foetal calf serum, 10% foetal calf serum or 10% foetal calf serum + 100 nM rapamycin. (A) Cell growth was
measured by haemocytometer; (B) apoptosis was measured by Annexin V labelling. Annexin V was measured only at 2 and 4 days on cells
grown in 0.5% FCS as there were insufficient cells remaining by 7 days. (C) Following 48 hours’ culture in RPMI with 10% foetal calf serum with or
without 100 nM rapamycin, cells were harvested, and processed for immunohistochemical analysis of γH2A.X foci. Cells treated for 2 hrs with
100 μg/ml etoposide were used as positive control in each assay. (For interpretation, an H score (reference 22) is a staining intensity score of 1–5
per cell for 100 cells, such that a score of 100 represents no staining and a score of 500 represents 100 completely damaged cells.). In each
experiment datapoints indicate mean and standard deviation of 3 independent assays.
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Thus, using an example from Figure 3B, roscovitine re-
duces unmanipulated cell number by 94% at 2 × IC50,
i.e. by doubling the IC50 concentration roscovitine man-
aged to deplete a futher 44% of cells, whereas araC man-
ages to deplete only a further 9% of cells when the IC50
concentration is doubled (Figure 3B). We established
that the RP2 inhibitor group of drugs were significantly
more effective at reducing cell number at 2 × IC50 than
the topoisomerase targeting agents or the nucleoside an-
alogues (P = 0.001 for topoisomerase targeting agents
and P < 0.001 for nucleoside analogues compared with
RP2 inhibitors in unmanipulated cells, P = 0.003 for both
comparisons in dormancy-enriched cells, Figure 3B.)
(DRB was used as a positive control for RP2 targeting
and is not a chemotherapeutic agent: its effects were
therefore not included in the statistical analysis).
Targeting of RNA polymerase II and RNA sythesis by RP2
inhibitors
Serine 2 of the elongation factor RNA Polymerase II
(RP2S2) is a molecular target of CDK9 [33]. Flavopiridol,
roscovitine and TG02 have multiple and diverse targets
in addition to RP2. We therefore measured whether
RP2S2 and RNA synthesis were being targeted at each
drug’s IC50. The existing literature, including our own
previous work with TG02 [10,13-15] indicated that in-
vestigation of these parameters after 6 hours of treat-
ment would show optimal effects. At this timepoint,
RP2S2 was significantly downregulated in dormancy-
enriched KG1a cells treated with RP2 inhibitors
(Figure 4A). RNA synthesis was greatly reduced at the
same timepoint (Figure 4B). A number of molecules
with short message and protein half-lives are depleted by
RNA polymerase II inhibitors [8], including several sur-
vival and cycle-related proteins [11-13,15]. MoreoverTG02, flavopiridol and roscovitine are all documented to
induce cell cycle arrest in G0/G1 [14,34,35], which we
confirmed in the KG1a model (data not shown), so it
was important to establish whether the decreases in cell
numbers relative to untreated controls were solely due
to growth inhibition or whether, as would be necessary
for dormant cell targeting, they also undergo apoptosis.
We observed apoptosis in all cases at the IC50 for DRB,
flavopiridol and TG02 (Figure 4C). Roscovitine had not-
ably little ability to induce apoptosis in the dormancy-
enriched cells (discussed below).
Sensitivity to RP2 inhibition in dormant CD34+ primary
leukaemic cells
We and others have previously documented the in vitro
toxicity of TG02 to bulk CD34 + CD38- primary AML
cells and demonstrated effective cell reduction at 100
nM [14,15]. The CD34 + CD38- subset is enriched for
dormant cells, but to address directly the question of
whether RP2 inhibitors target dormant primary cells, we
sought a flow cytometric assay that would combine a
dormancy marker with an apoptotic marker. Annexin V
is the standard, extremely sensitive, marker for apoptosis
in non-adherent cells, but its use in permeabilised cells
is problematic. Ki-67 is the standard marker for exclud-
ing, and thus identifying, dormant cells, but detects an
intracellular antigen and thus requires cells to be fixed
and permeabilised, which compromises Annexin V stain-
ing. We looked for a cell surface marker which would
discriminate between dormant and cycling cells and
could be used in conjunction with Annexin V to investi-
gate apoptosis in dormant cells. The absence of CD71,
the transferrin receptor, has been reported in dormant
lymphocytes and in cancer stem cells [36,37]. In prelim-
inary experiments, we established that cells which were
negative for CD71 (i.e. found in the lower two quadrants
Figure 2 Rapamycin induces key features of dormancy. Evaluation of cellular properties after treatment of KG1a cells with 100 nM rapamycin
for 48 hours. (A) RNA content: Flow cytometric dotplots indicate the percentage of cells which are low in RNA (Pyronin Y) as well as low in DNA
(7-AAD) and summary chart. In the summary chart, the RNA content of KG1a cells treated for 48 hours with etoposide, which induces
predominant G2/M arrest, are used as negative control. (B) The total RNA content of lysed cells, measured by spectrophotometry. (C) Flow
cytometric analysis of forward scatter as an indicator of cell size: representative histogram: dark-filled histogram = untreated cells, unfilled
histogram = rapamycin-treated cells and summary graph (instrument and voltage-dependent units). (D) Reduction of 2,3-bis(2-methoxy-4-nitro5-
sulfophenyl)-5-{(phenylamino)carbonyl}-2H-tetrazolium hydroxide to formazan: absorbance ratio (adjusted for cell count) after 48 hours as a
measure of mitochondrial metabolism. (E) Flow cytometric dichlorofluorescein diacetate as a measure of reactive oxygen species: example, dark-
filled histogram = untreated cells, unfilled histogram = rapamycin-treated cells, pale grey histogram = baseline; summary graph. In each
experiment datapoints illustrate mean and standard deviation of at least 3 independent assays. All P values are for comparisons between
untreated and rapamycin-treated cells.
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-negative (i.e. there were very few cells in the lower right
quadrants). CD71 negative cells can therefore be classi-
fied as dormant. To determine whether RP2 inhibition
induces apoptosis in dormant primary AML blasts, we
labelled in vitro-treated blasts for Annexin V and CD71.
Figure 5B shows our gating strategy. Using eight primary
samples, we found clear evidence of CD71neg cells in theAnnexin V lowpos subset of CD34+ AML blasts treated
with DRB, TG02 or flavopiridol (Figure 5C). When com-
pared with etoposide (which had not been effective in
targeting dormancy-enriched KG1a cells as shown in
Figure 3) a significantly higher proportion of apoptosing
cells was found in the CD71neg compartment after treat-
ment with all three RP2 inhibitors (P < 0.001 for DRB
and TG02, P = 0.007 for flavopiridol). It is important to
Figure 3 KG1a responses to chemotherapeutic agents. Un-manipulated KG1a cells and cells enriched for dormancy by rapamycin pre-
treatment were cultured in the presence of drugs for 48 hours whereupon net cell growth and survival was estimated using the 2,3-bis(2-
methoxy-4-nitro5-sulfophenyl)-5-{(phenylamino)carbonyl}-2H-tetrazolium hydroxide (XTT) assay. (A) Dose response curves in proliferating and
dormancy-enriched cells. Dark lines represent un-manipulated cells and light grey lines represent dormancy-enriched cells. (B) Percentage
decrease in viable cells at 2 × IC50. Dark bars represent unmanipulated cells and unfilled bars represent dormancy-enriched treated cells. Note
that for araC no IC50 for dormancy-enriched cells was reached, even at 20 times the IC50 of proliferating cells. In each experiment datapoints
indicate mean and standard deviation of at least 3 independent assays.
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icity of different agents but are selecting cells in which
apoptosis is occuring to determine in which compart-
ment (dormant or non-dormant) it is occuring. We
also took advantage of the fact that primary AML cells
in vitro show some spontaneous apoptosis, compared
to which all three RP2 inhibitors again were associatedwith a significantly greater proportion of apoptotic
cells in the CD71neg compartment (P < 0.001 for DRB,
P = 0.003 for TG02 and P = 0.01 for flavopiridol).
Roscovitine at doses up to 2 μM only reduced viable
cell concentration in a minority of primary samples
studied and we therefore have not documented results
with this agent.
Figure 4 Decreased RNA Polymerase II activity and RNA
synthesis in transcriptional RP2i-treated KG1a cells. Un-
manipulated KG1a cells and cells enriched for dormancy by
rapamycin pre-treatment were cultured with chemotherapy drugs,
each drug at its 48 hour IC50 concentration. (Daunorubicin was not
included in this set of experiments, due to interference from its
fluorescent properties). (A) Loss of serine 2-phosphorylated RNA
Polymerase II (RP2S2) was measured after 6 hours’ incubation of
proliferating and dormancy-enriched cells with chemotherapeutic
agents. For comparisons against untreated controls ** signifies P <
0.01; * signifies P < 0.05. (B) RNA synthesis was measured by 20 μM
5-ethynyl uridine incorporation for the final hour of a six hour
treatment with chemotherapeutic agents. For comparisons against
untreated controls ** signifies P < 0.01; * signifies P < 0.05.
(C) Apoptosis was measured using Annexin V after 18 hours. In each
experiment datapoints indicate mean and SEM of at least 3
independent assays.
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There is a paradox at the centre of chemoresistance re-
search, in that most anti-neoplastic drugs have been
designed to target proliferating cells as a surrogate for
tumour cells, and therefore the highly chemoresistant
dormant tumour cell does not fit into the mainstream
chemotherapeutic paradigm. In the AML field, a van-
guard of researchers has been investigating possible so-
lutions to this problem for the last twenty years and
more. From in vitro and animal model work, it is clear
that non-proliferating AML cells are resistant to ara-C,
and that chemosensitivity increases when cells are in-
duced into cycle by growth factor exposure [38-40].
However over a dozen clinical trials reflecting a great
deal of effort in applying this knowledge have yielded
equivocal results ([41] and references therein) and fresh
approaches are needed.
We reasoned that it would be useful to have in vitro
models to contribute to the search for ways of targeting
dormant leukaemia cells. Whilst there is a need for the
creation of suitable in vivo models to test longer- term
chemosensitivity in dormant leukaemia cells in an ap-
propriate microenvironment, we suggest that the value
of in vitro work is that it allows the comparison of a
broad range of drugs and allows for investigations of
their mechanisms of action, as is illustrated in the
current work.
The overwhelming evidence that activation of the
mTOR pathway pushes haematopoietic and leukaemic
cells out of dormancy [25-28] led us to investigate this
pathway. Moreover an elegant study published after the
current work was completed showed that AML cells
with an undifferentiated phenotype have prolonged
in vivo survival when mTOR activity is knocked out, and
that subsequent mTOR re-activation restores the leu-
kaemogenic potential of these cells [42]. In our study,
rapamycin slowed, but did not completely arrest growth
in KG1a cells (Figure 1A). However, in contrast to serum
Figure 5 Apoptosis in CD34+ dormant patient cells treated with RP2 inhibitors. (A) Ki-67/CD71 co-expression in CD34-gated primary AML
cells before culture. For Ki-67 and CD71 quadrant delineation, gating was carried out strictly such that 1% of isotype control fluorescence fell into
the positive quadrants. Flow cytometric dotplots of one sample and a diagram summarising mean ± standard deviation of target cell percentage
in each quadrant for the seven primary samples studied are shown. (B) An example of CD71 expression in CD34+ annexin V + AML blasts. Patient
cells were cultured for 16–18 hours with DRB, TG02, flavopiridol or etoposide. They were then labelled with CD71, CD45 and CD34, rinsed and
additionally labelled with Annexin V. CD71 expression was determined in CD34+ early apoptotic cells using the four part gating strategy detailed
in the Methods section. (i) Illustration of gating strategy showing how gates P1-P4 are applied; note especially that gates P1 and P4 are narrowed
to exclude late stages of apoptosis or necrosis in order to alleviate concern that CD71 might be shed. (ii) Flow cytometric histograms showing
CD71 expression in the cell subset gated on P1-P4 (MFI = mean fluorescence intensity). (C) CD71 negative cells shown as a percentage of total
early apoptotic cells from the P1-P4 subset of primary samples (n = 8 for TG02 and etoposide, n = 6 for DRB and flavopiridol). As primary samples
are heterogeneous, apoptosis-inducing drug concentrations were sample-specific (30-100 nM for TG02 and flavopiridol, 0.2-2 μM for etoposide,
20 μM for DRB). * The low proportions of CD71neg cells in untreated and etoposide-treated samples compared to RP2 inhibitor-treated samples
were statistically significant, as detailed in the text.
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dormancy, rapamycin did not cause apoptosis or DNA
damage (Figure 1) - an essential consideration for a
model in which the chemosensitivity of previouslyundamaged cells is to be assessed. We suggest that
rapamycin provides a useful model for dormancy be-
cause key features, i.e. low RNA, low metabolism and
low ROS, are enriched in the rapamycin-treated
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is of paramount importance, since cells characterised by
low RNA content retain the capacity to re-enter the cell
cycle and act as progenitors in vivo [30,31]. The RNAlow
characteristic of dormant cells is consistent with their
lack of proliferation and low metabolism [3], but for dor-
mant cancer cells this might be difficult to reconcile
with addiction to survival gene expression, leading us to
suggest that these cells may be sensitive to transcrip-
tional RP2 inhibitors. A publication several years ago
showed that flavopiridol targets non-cycling A549 cells
[43]. Flavopiridol and roscovitine were initially designed
to target cyclin dependent kinases that drive cell prolif-
eration, and it was only subsequently that the effects
were noted for both of these agents on down-regulating
survival molecules and inhibition of transcription
through inactivation of CDK9 [9,10,13,44]. TG02 has
been characterised more recently and, like the two other
agents, has multiple targets including cycling and tran-
scriptional CDKs [14]. In cell-free assays, TG02 has a
3nM IC50 for CDK9 [14]. As all three agents have mul-
tiple targets, we also used the RP2-specific inhibitor
DRB in our assays [4,32].
We have shown that transcriptional RP2 inhibitors are
better able than conventional agents to target
dormancy-enriched AML cells. We hypothesised that a
therapeutic window might exist for dormant cancer cells
because of the addiction of malignant cells to survival
gene expression [4,5]. Results from clinical trials with
roscovitine and flavopiridol [45] including a trial incorp-
orating flavopiridol in combination chemotherapy of
AML [46] have shown some efficacy at sub-toxic doses.
TG02 at tolerated doses induced lasting complete remis-
sions in an AML xenograft model [14] and at the time
of writing, is in Phase 1 trials for refractory and relapsed
leukaemias. We show that the specific transcriptional
RP2 inhibitor DRB as well as TG02, roscovitine and
flavopiridol down-regulate RNA Polymerase II activation
and RNA synthesis in both unmanipulated and
dormancy-enriched cells. We have not attempted to pick
out specific targets of RP2 down-regulation, as these are
multitudinous [8]. Functionally they tend to be genes in-
volved in rapid cellular responses, such as apoptosis reg-
ulators, mitosis regulators and genes involved in
signalling pathways such as several NFκB target genes
[8]. We have shown that apoptosis is induced by the spe-
cific RP2 inhibitor DRB and by flavopiridol and TG02
(Figures 4 and 5). Roscovitine appears to work mainly by
growth inhibition or a non-apoptotic mechanism of
death. It is noteworthy in this respect that gene expres-
sion profiling of agents inhibiting transcriptional CDKs
found that DRB and flavopiridol had similar broad activ-
ity, whereas roscovitine had a narrower range of activity
[8]. Moreover, in our hands, micromolar concentrationsof roscovitine were found to reduce viable cell concen-
tration in only 5/12 leukaemia samples studied in vitro
(data not shown) in contrast to a robust response to
TG02 at 100 nM [15].
To further validate our results indicating that RP2 in-
hibitors target dormancy-enriched KG1a cells, we sought
agreement for our findings in primary material. In con-
trast to cell lines, primary AML samples are enriched for
cells in G0 of the cell cycle [39]. We examined the extent
of apoptosis induced by RP2 inhibitors in dormant and
proliferative compartments of primary cells. As Annexin
V is a highly sensitive marker for early apoptosis in pri-
mary AML cells, we looked for a cell surface dormancy
marker that could be used in conjunction with Annexin
V to measure apoptosis in dormant compared to prolif-
erating cells. CD71 (the transferrin receptor) is absent in
un-stimulated peripheral blood lymphocytes, in some
cancer stem cells and in long term culture-initiating cells
from normal bone marrow [36,37,47]. Analysis of patient
samples co-labelled with CD71 and Ki-67 indicated that
CD71 is not expressed in dormant AML blasts (Figure 5).
Co-labelling of cells with CD71 and Annexin V clearly
indicated the contrast between the high proportion of
CD71neg apoptotic cells following treatment with DRB,
flavopiridol or TG02 and the high CD71 expression in
etoposide-treated apoptotic cells. Even compensating for
the plasma protein binding of the drug, the concentra-
tion of TG02 used in this experiment is readily achiev-
able in vivo in both animals [14] and humans (as
measured following oral administration in ongoing clin-
ical studies - FB, unpublished).Conclusion
In conclusion, we have shown that RP2 inhibitors effect-
ively target both KG1a cells enriched for dormancy by
mTOR inhibition and CD71neg primary leukaemia pa-
tient samples thus providing grounds for suggesting that
transcriptional RP2 inhibitors may be a useful class of
agent for targeting dormant cells thought to contribute
to relapses in leukaemia.Abbreviations
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